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BACKGROUND: Chronic heart failure (HF) is associated with altered 
signal transduction via β-adrenoceptors and G proteins and with reduced 
cAMP formation. Nucleoside diphosphate kinases (NDPKs) are enriched 
at the plasma membrane of patients with end-stage HF, but the functional 
consequences of this are largely unknown, particularly for NDPK-C. Here, 
we investigated the potential role of NDPK-C in cardiac cAMP formation and 
contractility.
METHODS: Real-time polymerase chain reaction, (far) Western blot, 
immunoprecipitation, and immunocytochemistry were used to study the 
expression, interaction with G proteins, and localization of NDPKs. cAMP 
levels were determined with immunoassays or fluorescent resonance 
energy transfer, and contractility was determined in cardiomyocytes (cell 
shortening) and in vivo (fractional shortening).
RESULTS: NDPK-C was essential for the formation of an NDPK-B/G protein 
complex. Protein and mRNA levels of NDPK-C were upregulated in end-
stage human HF, in rats after long-term isoprenaline stimulation through 
osmotic minipumps, and after incubation of rat neonatal cardiomyocytes 
with isoprenaline. Isoprenaline also promoted translocation of NDPK-C 
to the plasma membrane. Overexpression of NDPK-C in cardiomyocytes 
increased cAMP levels and sensitized cardiomyocytes to isoprenaline-
induced augmentation of contractility, whereas NDPK-C knockdown 
decreased cAMP levels. In vivo, depletion of NDPK-C in zebrafish embryos 
caused cardiac edema and ventricular dysfunction. NDPK-B knockout mice 
had unaltered NDPK-C expression but showed contractile dysfunction and 
exacerbated cardiac remodeling during long-term isoprenaline stimulation. 
In human end-stage HF, the complex formation between NDPK-C and 
Gαi2 was increased whereas the NDPK-C/Gαs interaction was decreased, 
producing a switch that may contribute to an NDPK-C–dependent cAMP 
reduction in HF.
CONCLUSIONS: Our findings identify NDPK-C as an essential requirement 
for both the interaction between NDPK isoforms and between NDPK 
isoforms and G proteins. NDPK-C is a novel critical regulator of β-
adrenoceptor/cAMP signaling and cardiac contractility. By switching from 
Gαs to Gαi2 activation, NDPK-C may contribute to lower cAMP levels and 
the related contractile dysfunction in HF.
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Heart failure (HF) is a common cause of death and disability.1 Altered signal transduction via β-adrenoceptors (βARs) and G proteins is a hall-
mark of chronic HF and contributes to impaired cardiac 
contractility.2,3 The exact molecular pathophysiological 
mechanisms contributing to contractile dysfunction in 
patients with HF are incompletely understood, and a 
better understanding of these processes is expected to 
foster the development of improved treatment options 
for patients with HF.3
The plasma-membrane content of nucleoside diphos-
phate kinases (NDPKs) is increased in patients with end-
stage HF,4 pointing to a potential role for NDPKs in HF. 
NDPKs represent a family of multifunctional proteins en-
coded by 10 human nm23 genes, of which the class I 
subfamily (consisting of NDPK-A, -B, -C, and -D) exerts 
enzymatic activity.5 NDPKs form heterohexamers and 
catalyze the transfer of γ-phosphate between nucleotide 
triphosphates and nucleotide diphosphates.6,7 NDPK-A 
and NDPK-B play a role in numerous cellular processes, 
often as part of larger signaling complexes. For exam-
ple, NDPK-B, but not NDPK-A, forms complexes with Gβγ 
dimers and acts as a protein histidine kinase that can 
activate cardiac G proteins in a receptor-independent 
manner.8–10 Nevertheless, our previous studies indicated 
that the complex between NDPK-B and G proteins cannot 
be reconstituted in vitro, suggesting that NDPK-B alone 
is insufficient to regulate G-protein signaling and that an 
as-yet unidentified key cofactor is required for the com-
plex formation of NDPK-B and G proteins at the plasma 
membrane.10
NDPK-C exerts enzymatic activity and is able to form 
heterohexamers with NDPK-A and NDPK-B.11 NDPK-C 
shares 72% homology with NDPK-A and NDPK-B but has 
an additional hydrophobic N-terminal domain (Figure I in 
the online-only Data Supplement), which could serve as 
a membrane anchor.12,13 NDPK-C is generally less abun-
dantly expressed than the major isoforms NDPK-A and 
NDPK-B11 but is highly enriched at the cardiac plasma 
membrane of patients with HF.14 Thus, NDPK-C might be 
the limiting factor targeting NDPK hexamers to membra-
nous G proteins and could be the most relevant NDPK 
isoform for cAMP regulation in the heart and for the pro-
gression of HF. However, the function of NDPK-C in the 
heart is unknown.
To investigate the role of NDPK-C in HF, we performed 
biochemical studies of NDPK-C and G-protein signaling in 
human and rat tissue samples, assessed the functional 
impact of NDPK-C on cAMP levels and cardiac contractil-
ity in isolated rat cardiomyocytes, and determined the 
in vivo effects of NDPKs on contractility in zebrafish and 
mice. We identify NDPK-C as the critical isoform for the 
regulation of G-protein function and cAMP levels in the 
heart, with important consequences for cardiac contrac-
tility. Our results show that NDPK-C can interact promiscu-
ously with both Gαs and Gαi proteins. The switch to Gαi2-
dominant regulation of G proteins by NDPK-C in human 
HF may contribute to the lower cAMP levels and impaired 
contractility characteristic of this clinical condition.
METHODS
A detailed overview of all methods is provided in the online-only 
Data Supplement. Key aspects are summarized below.
Tissue Procurement
Nonfailing human myocardium from the free wall of the left ven-
tricle was obtained from organ donors with no apparent heart 
disease and normal left ventricular function (determined by 
echocardiography) for whom no suitable heart transplant recip-
ients had been identified. Left ventricular myocardial samples 
of failing human hearts were obtained from patients with HF 
(New York Heart Association class III–IV) who underwent car-
diac transplantation. The experimental protocol was approved 
by the ethics review board of the University of Szeged Medical 
Center. Informed written consent was obtained for the use of 
nondiseased human hearts. All procedures conformed to the 
Helsinki Declaration of the World Medical Association.
Clinical Perspective
What Is New?
• We show for the first time that the nucleoside diphos-
phate kinase (NDPK)-C is required and indispensable 
for the interaction of NDPKs with both stimulatory Gs 
and inhibitory Gi proteins.
• NDPK-C–mediated targeting of NDPKs to the 
plasma membrane is increased in response to 
β-adrenoceptor stimulation and enhances intracel-
lular cAMP levels, cardiomyocyte contractility, and 
in vivo cardiac function.
• We provide novel mechanistic insights into remod-
eling of β-adrenoceptor signaling in heart failure 
(HF), showing that the HF-related increase in NDPK-
C expression may cause constitutive Gi-mediated 
inhibition of adenylyl cyclases, providing a plausible 
explanation for the lower cAMP levels in HF.
What Are the Clinical Implications?
• The increased NDPK-C membrane content in 
human HF could potentially counteract a fading 
β-adrenoceptor response in the early stages of 
HF by increasing the amount of Gαs proteins in the 
plasma membrane. However, by switching to Gαi2 
activation, NDPK-C may play a role in HF progres-
sion by reducing cAMP levels, typical for end-stage 
human HF.
• A better understanding of the molecular processes 
underlying altered G-protein signaling in HF may help 
to develop new HF therapies. We identify NDPK-C as 
a novel therapeutic target involved in the regulation 
of aberrant G-protein signaling and cardiac contrac-
tility in HF.
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Rat and Mouse Models of Isoprenaline 
Stimulation and Isolation of Rat Cardiomyocytes
Male Wistar rats received 4 days of either isoprenaline or 
vehicle administered via osmotic minipumps, as previously 
described.15 Male C57Bl/6 wild-type and NDPK-B knockout 
mice received the same treatment but for 7 days. All animals 
were anesthetized with 2% isoflurane inhalation and received 
carprofen (5 µg/kg SC) as analgesic. All procedures concern-
ing the care and use of animals were in accordance with institu-
tional guidelines (Az. G-12\10 Regierungspräsidium Karlsruhe, 
Germany, and Az. G10\65 LAVES Niedersachsen, Germany).
Generation of Recombinant Adenoviruses
Recombinant adenoviruses were generated as previously 
described.8,16–18 
mRNA Analysis, Transfection and Transduction, 
Membrane Fractionation, Western Blots, 
Immunoprecipitation, Far Western Blotting, and 
ATP/GTP Hydrolysis Assays
Details are provided in the online-only Data Supplement. The 
primers that were used are listed in Table I in the online-only 
Data Supplement.
Visualization of the Subcellular Localization of 
NDPK-C
Neonatal rat cardiomyocytes (NRCMs) and adult rat cardiomyo-
cytes (ARCMs) were cultured with serum-free medium on cov-
erslips and infected with Ad-Flag–NDPK-C. Twenty-four hours 
later, cells were stimulated with solvent or isoprenaline for up 
to 6 hours. The subcellular localization of NDPK-C was visual-
ized by confocal fluorescence microscopy.
Measurement of Intracellular cAMP
cAMP levels in NRCM or zebrafish lysates were assayed with 
a cAMP immunoassay.8,9,19 For cAMP assays in living cells, 
ARCMs were isolated and transduced with Epac2-camps 
adenovirus, as previously described,18 together with a control 
(LacZ) or NDPK-C–encoding adenovirus. Cells were stimulated 
with isoprenaline, forskolin, and 3-isobutyl-1-methylxanthine.
Fractional Shortening in ARCMs
ARCMs were infected with an adenovirus encoding enhanced green 
fluorescent protein (Ad-EGFP) or Ad-Flag–NDPK-C. Sarcomere 
shortening was assessed during field stimulation with a video-
based sarcomere-length detection system at 1.25 mmol/L 
Ca2+ in the bath solution.20
Zebrafish Maintenance, Morpholino Injection, 
Measurement of Fractional Shortening, and 
Histology
Zebrafish danio rerio were maintained under standard con-
ditions.21 Embryos at a 1-cell stage were injected with the 
indicated amounts of the NDPK-B or NDPK-C targeting mor-
pholino or a standard control oligonucleotide at the same 
concentration. Injections and analyses of fractional shortening, 
ventricular diameters, immunohistochemistry, and electron 
microscopy were performed as previously described.19,21
Statistics
Results are presented as mean±SEM. Normality was assessed 
with the D’Agostino and Pearson omnibus test. The Mann-
Whitney test (for nonnormally distributed data or data with too 
few points to assess normality), an unpaired 2-tailed Student t 
test, or 1- or 2-way ANOVA followed by a post hoc Bonferroni or 
the Tukey test was used to compare means between groups. 
Values of P<0.05 were considered statistically significant.
RESULTS
Interactions Among NDPK-C, NDPK-B, and G 
Proteins
NDPK-C forms hetero-oligomers with NDPK-A and NDPK-
B.11 Moreover, NDPK-B/Gβγ complexes regulate G-protein 
activity and membrane content in cardiomyocytes.8,19,22 
Therefore, we assessed whether NDPK-C is involved in 
the complex formation of NDPKs with G proteins using 
far Western blotting.10 When the purified heterotrimeric 
G protein transducin (Gtαβγ)
10 was spotted on cellulose 
membranes and incubated with lysates of control NRCMs 
or NRCMs with adenovirus-mediated overexpression of 
NDPK-B, no direct interaction occurred (Figure 1A). In con-
trast, purified Gtαβγ showed a strong direct interaction 
with exogenous Flag–NDPK-C, detected with an anti-Flag 
antibody, in Flag–NDPK-C overexpressing NRCMs. The pu-
tative interaction between NDPK-B and endogenous NDPK-
C was confirmed with recombinant NDPK-B spotted on 
cellulose membranes and incubated with NRCM lysates. 
Adenovirus-mediated overexpression of NDPK-C further 
increased the interaction between NDPK-B and NDPK-C 
(Figure 1A). Furthermore, raising the relative NDPK-C con-
tent in NRCM lysates with a constant overexpression of 
NDPK-B (multiplicity of infection, 100) by increasing the 
multiplicity of infection of the Ad-Flag–NDPK-C virus from 
0 to 100 produced a concentration-dependent increase in 
the binding of NDPK-B to Gtαβγ (Figure 1B). These data 
suggest that NDPK-C is essential for the previously de-
tected complex formation between NDPK-B and Gβγ.
ATP/GTP hydrolysis assays were used to analyze the 
effects of NDPK-B and NDPK-C on the activation of Gtαβγ, 
as monitored by the GTPase activity of its Gα subunit, 
which does not hydrolyze ATP. Thus, only in the presence 
of NDPKs can the radiolabeled phosphate group from 
[32P]ATP be transferred to GDP, forming [32P]GTP, the ap-
propriate Gtα-GTPase substrate. The Gtαβγ preparation 
exhibited some ATP hydrolysis capacity, as indicated by 
the inhibitory effect of the NDPK activity–suppressing 
uridine 5'-diphosphate (UDP; Figure 1C).23 This basal 
activity can be attributed to the NDPKs copurified in bo-
vine Gtαβγ.
10 Addition of purified recombinant NDPK-C, 
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Figure 1. Nucleoside diphosphate kinase (NDPK)-C interacts directly with NDPK-B and G proteins.  
A, Representative far Western blots: The purified heterotrimeric G protein transducin (Gtαβγ) was incubated with lysates  
of control neonatal rat cardiomyocytes (NRCMs) or NRCMs overexpressing NDPK-B (left) or flag-tagged NDPK-C (Continued )
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but not NDPK-B, significantly increased ATP hydrolysis. 
Combining both NDPKs produced a significant additional 
increase. All increments in ATP hydrolysis were sensi-
tive to UDP, confirming the involvement of the enzymatic 
activity of NDPKs.23 Similar results were obtained when 
GTP hydrolysis was measured (Figure II in the online-only 
Data Supplement), supporting an NDPK-C–dependent 
activation of Gtαβγ.
To investigate the interaction between individual G-
protein family members and NDPK-B or NDPK-C, purified 
NDPK-B and NDPK-C were spotted on cellulose mem-
branes and incubated with lysates of mouse embryonic 
fibroblasts. Binding of G proteins to these NDPKs was 
subsequently detected with specific antibodies against 
Gβ1, Gβ2, Gαq, Gαs, and Gαi2. Purified NDPK-B showed 
no direct interaction with any tested G-protein subunit, 
whereas NDPK-C strongly interacted with all G-protein 
subunit compositions tested (Figure 1D). To test whether 
NDPK-C alone can regulate G proteins, independently of 
NDPK-B, mouse embryonic fibroblasts of NDPK-A/NDPK-
B double-knockout mice were used. Cardiac myocytes 
of these animals were not available because they die 
shortly after birth.24 Adenovirus-mediated overexpres-
sion of Flag–NDPK-C in NDPK-A/NDPK-B double-knock-
out mouse embryonic fibroblasts significantly increased 
the membrane content of Gαs and Gβ1 (Figure 1E), 
showing that NDPK-C alone is sufficient to regulate G 
proteins. We then determined whether Gαs and Gαi2 
compete for binding to NDPK-C. Different amounts of 
NRCM lysates overexpressing Gβ1γ2, Gαs, or Gαi2 (Figure 
III in the online-only Data Supplement) were combined to 
obtain specific ratios of Gαi2 to Gαs, and the interaction 
between recombinant NDPK-C and Gαs or Gαi2 proteins 
was determined with Far Western blots. As expected,8,9 
recombinantly expressed Gαs or Gαi2 in NRCM lysates 
bound to NDPK-C in the presence of sufficient amounts 
of recombinantly expressed Gβ1γ2 (Figure 1F). However, 
increasing the levels of Gαi2 with a fixed amount of Gαs 
produced a ratio-dependent decrease in the amount of 
Gαs binding to NDPK-C (Figure 1F, left). Likewise, in-
creasing Gαs levels for a fixed Gαi2 amount produced a 
ratio-dependent decrease in the amount of Gαi2 binding 
to NDPK-C (Figure 1F, right). Together, these data strong-
ly suggest that NDPK-C is essential for both complex 
formation of NDPKs with G proteins and the resulting 
G-protein activation. Moreover, Gαs and Gαi2 proteins di-
rectly compete for binding to NDPK-C, and even modest 
changes in the Gαi2 to Gαs ratio apparently modulate the 
interaction between NDPK-C and G proteins.
NDPK-C Levels Increase in Response to βAR 
Stimulation
Using human tissue samples from a previous study,14 we 
found a significantly increased membrane protein con-
tent of NDPK-A, NDPK-B, and NDPK-C isoforms in failing 
versus nonfailing hearts (Figure IV in the online-only Data 
Supplement), pointing to a role of NDPKs in HF patho-
physiology. mRNA levels of NDPK-C, but not NDPK-A and 
NDPK-B, were significantly increased in HF hearts (Figure 
IV in the online-only Data Supplement), suggesting a se-
lective transcriptional upregulation of NDPK-C in human 
HF. Patients with HF show a hyperactive sympathetic 
nervous system with elevated plasma catecholamine 
levels and subsequent chronic activation of βARs. There-
fore, we asked whether chronic βAR stimulation contrib-
utes to the NDPK-C upregulation in HF. Compared with 
saline-infused controls, chronic in vivo βAR stimulation 
with isoprenaline in rats induced a significant 5- and 14-
fold increase in NDPK-B and NDPK-C mRNA content, re-
spectively (Figure 2A) but enhanced the protein levels of 
NDPK-C only (Figure 2B). Thus, the increased expression 
of NDPK-C in patients with HF could directly result from 
the chronic activation of βARs.
As shown in Figure 2C, NDPK-C and Gαs could be 
detected in Gβ precipitates from rat ventricular tissue 
lysates, indicating that NDPK-C interacts with the hetero-
trimeric G protein. Furthermore, the amount of NDPK-
C and Gαs coimmunoprecipitating with Gβ apparently 
increased after long-term isoprenaline treatment, sug-
Figure 1 Continued. (middle). Recombinant NDPK-B was incubated with lysates of control NRCMs (left) or NRCMs overex-
pressing flag-tagged NDPK-C. NDPK-C was detected with an antibody against NDPK-C (right). B, Representative far Western 
blot and quantification of the NDPK-B/Gtαβγ interaction in NRCM lysates infected with Ad-NDPK-B (multiplicity of infection [MOI], 
100) and varying combinations of an adenovirus encoding enhanced green fluorescent protein (Ad-EGFP) and Ad-Flag–NDPK-C 
(total combined MOI, 100). *P<0.05 vs 100-MOI Ad-EGFP (0-MOI Ad-Flag–NDPK-C). C, ATP hydrolysis by Gtαβγ (1 µmol/L) and 
Gtαβγ plus NDPK-B (1 µmol/L), plus NDPK-C (0.25 µmol/L), or plus NDPK-B and NDPK-C determined by the amount of [
32P]
Pi released in the absence or presence of 500 µmol/L uridine 5'-diphosphate (UDP). *P<0.05 vs Gtαβγ. 
#P<0.05 vs without 
UDP. §P<0.05 vs Gtαβγ+NDPK-C. D, Far Western blot analysis of purified NDPK-B and NDPK-C incubated with cell lysates from 
mouse embryonic fibroblasts (MEFs). G-protein subunits were subsequently detected with antibodies against Gβ1, Gβ2, Gαq, 
Gαs, and Gαi2. E, Representative Western blots and quantification of Gβ1, Gαs, Flag–NDPK-C, and β-actin in membrane fractions 
of NDPK-A/NDPK-B double-knockout MEFs infected with Ad-EGFP or Ad-Flag–NDPK-C. *P<0.05 vs Ad-EGFP. F. Far Western blot 
analysis of NDPK-C incubated with mixtures of lysates of NRCMs overexpressing Gβ1γ2, Gαs, or Gαi2 to obtain specific ratios of 
both G proteins (indicated below the corresponding bars). The interaction between NDPK-C and Gαs or Gαi2 was subsequently 
quantified (bars). *P<0.05 vs incubation with lysates from NRCMs overexpressing only Gαs plus Gβ1γ2 (left) or Gαi2 plus Gβ1γ2 
(right, second bar in each chart).
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gesting that isoprenaline not only increases NDPK-C ex-
pression but also may enhance the interaction between 
NDPK-C and G proteins. To verify that these alterations 
occur in cardiomyocytes, NRCMs were incubated with 
isoprenaline or solvent for 7 days in vitro. Consistent with 
the data obtained in human ventricular tissue samples, 
both mRNA content and protein expression of NDPK-C 
were increased by in vitro βAR stimulation, whereas the 
expression of NDPK-B remained unchanged (Figure 2D 
and 2E). The interaction between NDPK-B and Gβγ was 
confirmed in NRCMs and was enhanced by overexpres-
sion of NDPK-C (Figure 2F), suggesting that NDPK-C is 
critical for the interaction between NDPK-B and Gβγ in 
cardiomyocytes.
Subcellular Localization of NDPK-C After βAR 
Stimulation
NDPK-C was detected predominantly in the cytosol of 
unstimulated NRCMs. In vitro stimulation of NRCMs with 
isoprenaline for 6 hours significantly increased the pro-
tein levels of NDPK-C at the plasma membrane, with a 
membrane/cytosol fluorescence ratio of 2.26±0.22 
(n=27) versus 0.83±0.10 (n=28) under control condi-
Figure 2. Nucleoside diphosphate 
kinase (NDPK)-C expression is 
increased after long-term iso-
prenaline (ISO) administration.  
A and B, NDPK-B and NDPK-C in con-
trol rats or rats after 4 days of ISO 
administration (2.4 mg·kg−1·d−1). A, 
mRNA content determined by quan-
titative polymerase chain reaction in 
ventricular samples. Hydroxymethyl-
bilane synthase (HMBS) was used as 
housekeeping gene for normalization. 
B, Representative Western blots (top) 
and quantification of protein expres-
sion (bottom) in ventricular lysates. 
GAPDH was used as loading control. 
C, Immunoprecipitation (IP) of Gβ in 
ventricular lysates of control rats or 
rats after 4 days of ISO administra-
tion. Coimmunoprecipitated proteins 
were detected with antibodies against 
Gαs and NDPK-C. IB indicates im-
munoblot D and E, Similar to A and 
B for control neonatal rat cardio-
myocytes (NRCMs) or NRCMs after 
7 days of incubation with ISO (1.0 
μmol/L). Data are shown relative to 
controls (Ctl). Numbers in bars indi-
cate number of samples. *P<0.05 vs 
corresponding control. F, Immunopre-
cipitation of NDPK-B in lysates from 
NRCMs infected with an adenovirus 
encoding enhanced green fluorescent 
protein (Ad-EGFP) or Ad-Flag–NDPK-C, 
for 48 hours. Coimmunoprecipitated 
proteins were detected with antibod-
ies against NDPK-B and Gβ.
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tions (P<0.001; Figure 3A–3C), pointing to translocation 
of NDPK-C to the plasma membrane by isoprenaline in 
addition to the transcriptional upregulation of NDPK-C 
observed after 7 days of isoprenaline treatment. The 
interaction between NDPK-C and Gβγ determined by 
coimmunoprecipitation (Figure V in the online-only Data 
Supplement), as well as the membrane content of Gαs 
(Figure 3D), were also increased. Taken together, these 
data support the formation of NDPK-C, NDPK-B, and G-
protein complexes, resulting in their enrichment at the 
plasma membrane after isoprenaline stimulation, and 
point to a potential role of NDPK-C in the regulation of 
cellular cAMP synthesis.
NDPK-C Modulates cAMP and Cardiomyocyte 
Contractility
To study the functional consequences of NDPK-C regula-
tion on cellular cAMP levels, NDPK-C protein levels were 
reduced by siRNA-mediated knockdown (si–NDPK-C; Fig-
ure 4A) or increased by adenovirus-mediated overexpres-
sion (Ad-Flag–NDPK-C; Figure 4B). NDPK-C expression 
was reduced by 34.8±6.4% with si–NDPK-C compared 
with si-control (Figure 4C), but the use of Ad-Flag–NDPK-
C and corresponding anti-Flag antibody precluded quan-
tification of NDPK-C overexpression levels. Modification 
of NDPK-C protein levels produced parallel changes in 
Figure 3. Gαs and nucleoside 
diphosphate kinase (NDPK)-C 
membrane content are enhanced 
after short-term isoprenaline 
(ISO) administration.  
A, Confocal microscopy showing 
Flag–NDPK-C (red), DAPI (blue), and 
enhanced green fluorescent protein 
(EGFP; green) in neonatal rat cardio-
myocytes (NRCMs) overexpressing 
Flag–NDPK-C (multiplicity of infection, 
50) under control conditions (Ctl; top 
row) or after 6 hours of stimulation 
with 1.0 μmol/L ISO (6h-ISO; bottom 
row). B, Line profiles (colored lines) 
of Flag–NDPK-C in 8 representative 
NRCMs in Ctl (left) or 6h-ISO groups 
(right) and average line profiles 
across all NRCMs (black lines). C, 
Fluorescence intensity in membrane 
region (first and last 15% of line pro-
file) vs cytosol in the Ctl and 6h-ISO 
groups. D, Representative Western 
blots of Gβ and Gαs (top) and quan-
tification of Gαs-protein expression 
(bottom) in membrane fractions from 
Ctl or 6h-ISO NRCMs. β-Actin was 
used as loading control. Numbers 
in bars indicate number of samples. 
*P<0.05 vs Ctl.
 by guest on February 28, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
Abu-Taha et al
February 28, 2017 Circulation. 2017;135:881–897. DOI: 10.1161/CIRCULATIONAHA.116.022852888
Gαs, with significantly reduced Gαs levels in lysates of 
si–NDPK-C NRCMs, and increased Gαs membrane con-
tent in Ad-Flag–NDPK-C NRCMs (Figure 4C). Knockdown 
of NDPK-C expression also significantly reduced cAMP 
levels, whereas NDPK-C overexpression enhanced cAMP 
content (Figure 4D). Isoprenaline induced a dose-depen-
dent increase in cAMP content with a >50-fold increase 
in cAMP levels compared with control conditions after 
maximal stimulation (Figure 4E). The increase in isopren-
aline-induced cAMP content was significantly reduced in 
si–NDPK-C NRCMs (Figure 4E) but further enhanced by 
overexpression of NDPK-C (Figure 4F). These findings es-
tablish a causal relationship between NDPK-C content at 
the plasma membrane and cellular cAMP levels in NRCMs.
We next determined whether NDPK-C also regulates 
G proteins and cAMP in ARCMs. NDPK-C levels at the 
plasma membrane were significantly increased after 6 
hours of isoprenaline stimulation in ARCMs (Figure 5A and 
5B). To assess the effects of NDPK-C in living ARCMs, we 
compared cAMP formation and fractional shortening8,20 
in ARCMs overexpressing NDPK-C with control ARCMs 
overexpressing EGFP or LacZ. Isoprenaline-induced cAMP 
levels were quantified in isolated ARCMs via fluorescent 
resonance energy transfer with an Epac-derived cAMP 
sensor.25,26 Stimulation of control ARCMs with isoprena-
line produced 55±3% of the maximal cAMP response 
achieved by direct stimulation of adenylyl cyclases with 
forskolin in the presence of the phosphodiesterase inhibi-
tor 3-isobutyl-1-methylxanthine (Figure 5C). In NDPK-C–
overexpressing ARCMs, the isoprenaline-induced cAMP 
response was significantly increased to 70±3% of the 
maximal cAMP response (Figure 5C).The isoprenaline 
concentrations producing half-maximal cell shortening 
were significantly higher in the control (4.5±0.9 nmol/L) 
than in NDPK-C–overexpressing ARCMs (0.8±0.1 nmol/L; 
Figure 5D), suggesting that the NDPK-C–induced increase 
in cAMP affects cardiomyocyte contraction by sensitizing 
single-cell shortening to βAR stimulation.
Knockdown of NDPK-C Modulates Contractility in 
Zebrafish
To analyze whether NDPK-C modulates contractility in 
vivo in a vertebrate organism, we performed morpholino-
mediated knockdown of NDPK-C in zebrafish embryos. 
The injection of 300 µmol/L morpholino–NDPK-C caused 
Figure 4. Nucleoside diphosphate 
kinase (NDPK-C) modulates cAMP 
levels.  
A and B, Representative Western blots of 
Gβ, Gαs, and NDPK-C or Flag–NDPK-C in 
lysates from neonatal rat cardiomyocytes 
(NRCMs) transfected with siRNA (si)-Ctl or 
si–NDPK-C (96 hours) and in membrane 
fractions from NRCMs infected with an 
adenovirus encoding enhanced green 
fluorescent protein (Ad-EGFP) or Ad-Flag–
NDPK-C (multiplicity of infection, 500 for 
48 hours). β-Actin levels served as load-
ing control. C, Quantification of NDPK-C 
protein levels normalized to β-actin in 
si-Ctl vs si–NDPK-C (left) or Gαs-protein 
levels from A and B normalized to β-actin 
relative to corresponding controls (right). 
D, cAMP levels in NRCMs transfected 
with si-Ctl or si–NDPK-C and NRCMs 
infected with Ad-EGFP or Ad-Flag–NDPK-C 
NRCMs in the presence of 1.0 mmol/L 
3-isobutyl-1-methylxanthine (IBMX) 
and 1.0 μmol/L propranolol. E and F, 
Isoprenaline (ISO)-induced cAMP levels in 
NRCMs with si-RNA–mediated reduction 
in NDPK-C (left), or in NRCMs overex-
pressing NDPK-C (right) in the presence 
of 1.0 mmol/L IBMX and the indicated 
ISO concentration compared with 
corresponding controls. Numbers in bars 
indicate number of samples. *P<0.05 
vs si-Ctl. #P<0.05 vs Ad-EGFP.
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a loss of NDPK-C protein levels, resulting in phenotypic 
alterations, including reduced cardiac pump function 
and pericardial edema, compared with zebrafish inject-
ed with a control morpholino at 72 hours after fertiliza-
tion (Figure 6A and Supplementary Videos I and II in the 
online-only Data Supplement). NDPK-C morphant hearts 
had a normal morphology of endocardial and myocardial 
cell layers and a regular expression of atrial and ven-
tricular myosin heavy chains (Figure VIA–VID in the online-
only Data Supplement). In addition, electron microscopy 
revealed no differences in the ultrastructure of sarco-
meres, z line, and thick and thin filaments (Figure VIE 
and VIF in the online-only Data Supplement). Therefore, 
the structural development of the NDPK-C morphant 
hearts appears to be unhampered. Functionally, deple-
tion of NDPK-C resulted in decreased basal cAMP levels 
(Figure 6B), similar to that reported previously for zebraf-
ish with knockdown of NDPK-B.19 Ventricular fractional 
Figure 5. Consequences of nucleoside diphosphate kinase (NDPK)-C modulation in adult rat cardiomyocytes 
(ARCMs).  
A, Confocal microscopy showing Flag–NDPK-C (red), DAPI (blue), and enhanced green fluorescent protein (EGFP; green) in ARCMs 
overexpressing Flag–NDPK-C (multiplicity of infection [MOI], 50) under control conditions (Ctl; top row) or after 6 hours of stimula-
tion with ISO (6h-ISO; 1.0 μmol/L; bottom row). B, Line profiles of Flag–NDPK-C in 4 representative ARCMs (colored lines) in 
Ctl (top left) or 6h-ISO groups (top right) and average line profiles across all ARCMs (black lines). Bar chart shows fluorescent 
intensity in membrane region (first and last 15% of line profile) vs cytosol in the Ctl and 6h-ISO groups. C, Representative fluores-
cent resonance energy transfer (FRET; cyan fluorescent protein/yellow fluorescent protein [CFP/YFP]) ratio traces recorded from 
control and Ad-Flag–NDPK-C–overexpressing ARCMs (MOI, 300) expressing the cAMP sensor Epac2-camps after stimulation with 
ISO (100 nmol/L) and subsequent maximal stimulation of cAMP levels by forskolin (10 μmol/L) and 3-isobutyl-1-methylxanthine 
(IBMX; 100 μmol/L). Decreases in the FRET ratio represent increases in intracellular cAMP. The magnitude of the cAMP response 
to ISO as a percent of maximal response induced by forskolin plus IBMX in control and NDPK-C–overexpressing ARCMs is shown 
on the right. n=16 to 17 cells obtained from 2 independent infections. D, Concentration-dependent increase in relative fractional 
shortening of isolated ARCMs infected with Ad-EGFP or Ad-Flag–NDPK-C (MOI, 300) after short-term stimulation with the indicated 
concentrations of ISO. n=29 to 42 cells per condition from 3 independent infections. Inset shows the EC50 of ISO-induced aug-
mentation of cellular fractional shortening. Numbers in bars indicate number of samples. *P<0.05 vs corresponding control.
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shortening was progressively reduced from 26.0±1.9% 
at 48 hours after fertilization to 7.4±1.7% at 72 hours 
after fertilization in NDPK-C morphants, whereas frac-
tional shortening remained stable in morpholino-control 
zebrafish (Figure 6C). To evaluate synergism between 
NDPK-C and NDPK-B in vivo, a partial knockdown of 
NDPK-B and/or NDPK-C was performed with the use of 
low morpholino concentrations, and ventricular fraction-
al shortening was assessed. Morpholino–NDPK-B (125 
µmol/L) or morpholino–NDPK-C (150 µmol/L) alone did 
not significantly impair ventricular function, whereas 
their combination severely reduced fractional shortening 
(Figure 6D). To analyze whether an increased NDPK-B 
expression can substitute for the loss of NDPK-C, we 
overexpressed NDPK-B, an approach that previously 
rescued the phenotype caused by morpholino-mediated 
knockdown of NDPK-B.19 Compared with controls, NDPK-
C morphants frequently showed phenotypic abnormali-
Figure 6. Nucleoside diphosphate kinase (NDPK)-C knockdown in zebrafish reduces ventricular contractility.  
A, Lateral view of representative zebrafish larvae injected with 300 µmol/L control or NDPK-C morpholinos (MO-Ctl and 
MO–NDPK-C, respectively) 72 hours post fertilization (hpf; left). NDPK-C–depleted embryos develop a pericardial edema 
(arrow) as a result of cardiac dysfunction. Right, Representative Western blot of NDPK-C and β-actin as loading control. B, 
cAMP levels in zebrafish injected with control or NDPK-C morpholinos 72 hpf in the presence of 3-isobutyl-1-methylxanthine 
(IBMX; 1.0 mmol/L). Shown is the average of 2 independent cAMP determinations in fish lysates. Numbers in bars indicate 
the total number of fish used for the determination of this value. C, In vivo fractional shortening of zebrafish ventricle in 
zebrafish injected with control or NDPK-C morpholinos at 48, 60, and 72 hpf. *P<0.05 vs control morpholinos (repeated-
measures 2-way ANOVA). D, In vivo fractional shortening of zebrafish ventricle in zebrafish injected with control, NDPK-B 
(125 µmol/L), NDPK-C (150 µmol/L), or both NDPK-B (125 µmol/L) and NDPK-C (150 µmol/L) morpholinos at 72 hpf. 
*P<0.05 vs control morpholinos. E, Percentage of zebrafish developing morphological abnormalities under control condi-
tions and after knockdown of NDPK-C, knockdown of NDPK-C with NDPK-B overexpression, or NDPK-B overexpression 
alone. *P<0.05 vs control.
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ties (eg, pericardial edema or impaired cardiac function; 
Figure VII in the online-only Data Supplement). NDPK-B 
overexpression in NDPK-C knockdown embryos did not 
reduce the incidence of these phenotypic abnormalities 
(Figure 6E). Thus, in accordance with the in vitro data, 
NDPK-C is apparently indispensable for the complex for-
mation between NDPKs and G proteins, which is involved 
in cAMP formation and the subsequent alterations in ven-
tricular contractility in vivo.
NDPK-B–Deficient Mice Are Prone to Cardiac 
Dysfunction
To verify the importance of the complex formation of 
NDPK-C, NDPK-B, and G proteins described above for 
cardiac function in mammals, we took advantage of 
NDPK-B knockout mice.27 These mice are viable, without 
obvious phenotype, and have a normal life span. The 
loss of NDPK-B does not alter the expression of NDPK-C 
in the heart of these mice (Figure VIII in the online-only 
Data Supplement). Nevertheless, at the age of 5 months, 
they start to develop cardiac dysfunction, as revealed 
by decreased fractional shortening (Figure 7A). To test 
whether the complex formation of NDPK-B with NDPK-C 
and G proteins is functionally relevant in the response to 
chronic βAR stimulation in the mammalian heart, we sub-
jected these mice to the long-term isoprenaline stimula-
tion protocol we used in rats (Figure 2A) and studied car-
diac contractility and remodeling. As shown in Figure 7B 
through 7D, long-term isoprenaline treatment decreased 
fractional shortening more strongly in NDPK-B knock-
out mice than in wild-type controls. In addition, NDPK-B 
knockout  mice were more susceptible to isoprenaline-in-
duced cardiac hypertrophy and fibrosis. Taken together, 
these data indicate that the complex formation of NDPKs 
with Gαs proteins, which apparently requires the pres-
Figure 7. Ablation of nucleoside 
diphosphate kinase (NDPK)-B 
reduces cardiac function in 
aging mice and aggravates 
catecholamine-induced cardiac 
remodeling in young mice.  
A, Fractional shortening (FS) of 
5-month-old male wild-type (WT) and 
NDPK-B knockout (NDPK-B KO) mice 
calculated from echocardiographic 
analysis in conscious animals. B and 
C, Two-month-old male WT and NDPK-B 
KO mice were either subjected to 
control conditions or treated with 
isoprenaline (ISO; 30 mg·kg−1·d−1) 
for 7 days via osmotic minipumps. 
B, FS in conscious animals at day 7 
of the treatment. C, Quantification of 
hypertrophic growth by ratios of heart 
weight (HW) to body weight (BW). D, 
Representative images of explanted 
hearts. E, Quantification of fibrotic 
remodeling by Sirius Red/Fast Green 
Collagen staining of paraffin-embed-
ded heart sections normalized to total 
tissue area. F, Representative image 
of collagen-stained (magenta) heart 
sections. *P<0.05 vs respective 
control. #P<0.05 versus WT, 2-way 
ANOVA with Bonferroni correction.
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ence of both NDPK-B and NDPK-C, is beneficial during 
catecholamine-induced cardiac stress and protects the 
heart from an early onset of remodeling.
NDPK-C Causes a Switch From Gαs- to Gαi-
Predominant Signaling in Human HF
The data presented so far identify NDPK-C, by mediating 
complex formation and membrane targeting of NDPK-
B and Gαs, as a regulator with stimulatory effects on 
cAMP levels and contractility. However, the increased 
expression of NDPK-C in human HF appears at odds with 
the reduced contractility observed in patients with HF. 
On the other hand, our far Western blots indicate that 
NDPK-C, but not NDPK-B, interacts with both Gαs and 
Gαi, and the ratio of these proteins determines which G 
protein is preferentially bound (Figure 1D and 1F). There-
fore, we hypothesized that NDPK-C may switch from 
Gαs- to Gαi-predominant signaling in human HF, thereby 
contributing to the lower cAMP levels and reduced car-
diomyocyte contractility. To address this hypothesis, we 
analyzed NDPK-B and NDPK-C expression in ventricular 
tissue samples from a separate patient cohort. In accor-
dance with the data obtained in the previous collective,14 
NDPK-B and NDPK-C protein levels were significantly in-
creased in tissue lysates of patients with HF compared 
with healthy donor hearts (Figure 8A). The Gαi2- and Gαs-
protein expression in membrane fractions of patients 
with HF appeared to be slightly increased (20%) and 
decreased (−15%), respectively, without reaching statis-
tical significance (Figure 8A and Figure IXA in the online-
only Data Supplement).
Next, we assessed the interactions among NDPK-C, 
Gαi2, and Gαs in ventricular tissue lysates of control 
samples and those from patients with HF using coim-
munoprecipitation. The NDPK-C content of the Gαi2 pre-
cipitates was increased 2.8±0.8-fold in patients with HF 
(P=0.11), whereas the NDPK-C content in the Gαs pre-
cipitates of HF samples was decreased to 0.54±0.14-
fold of nonfailing controls (P=0.07; Figure IXB in the 
online-only Data Supplement). Conversely, the amount 
of Gαi2 that coprecipitated with NDPK-C was increased 
2.39±0.35-fold (P<0.05), whereas the amount of Gαs 
that coprecipitated with NDPK-C was decreased to 
0.55±0.08 of nonfailing controls (P<0.05) in human 
HF, pointing to a switch in the interaction of NDPK-C 
from Gαs to Gαi2 (Figure 8B). cAMP levels were signifi-
cantly reduced by 42% in patients with HF (Figure 8C), 
consistent with previous results.28 To determine wheth-
er the switch in NDPK/G-protein signaling affects cAMP 
levels, NRCMs overexpressing EGFP, NDPK-C, Gαi2,, 
or NDPK-C plus Gαi2 (Figure 8D) were incubated with 
increasing concentrations of isoprenaline. Overexpres-
sion of NDPK-C increased the basal and isoprenaline-in-
duced cAMP levels in NRCMs. In contrast, overexpres-
sion of Gαi2 reduced the basal cAMP content and the 
isoprenaline-induced increase in cAMP levels compared 
with EGFP-expressing controls (Figure 8E and 8F). It is 
notable that overexpression of both NDPK-C and Gαi2 
further reduced basal cAMP levels and isoprenaline-
induced cAMP production compared with Gαi2 overex-
pression alone (Figure 8E and 8F). These data indicate 
that the HF-related increase in NDPK-C and the stronger 
interaction between Gαi2 and NDPK-C (Figure 8A and 
8B) amplify the inhibitory effects of Gαi2 proteins on 
cardiomyocyte cAMP levels and positions NDPK-C as a 
novel, potentially critical regulator of Gαi-protein signal-
ing and cellular cAMP in human HF.
DISCUSSION
In the present study, we identified NDPK-C as an es-
sential and indispensable component of the interaction 
between NDPKs and G proteins. NDPK-C anchors these 
complexes at the plasma membrane, thereby being an 
important regulator of cAMP levels and cardiomyocyte 
contractility. We also discovered that a switch from pre-
dominantly Gαs stimulation to Gαi signaling by NDPK-C 
in human HF might cause the lower cAMP levels in pa-
tients with HF. Together, our findings identify NDPK-C as 
a novel critical regulator of βAR/cAMP signaling that may 
contribute to contractile dysfunction in HF.
G-Protein Signaling in HF
HF induces complex remodeling, with changes in G-pro-
tein signaling as a hallmark of this remodeling process. 
Long-term sympathetic stimulation results in desensiti-
zation of βARs, including reduced expression of β1ARs 
and upregulation of inhibitory G-protein–coupled recep-
tor kinases.29,30 In addition, the expression and activity of 
inhibitory Gαi proteins are increased ≈30% in end-stage 
HF,31,32 and a shift from a prevalence of Gαs-mediated 
adenylyl cyclase stimulation to Gαi-mediated inhibition 
of adenylyl cyclases through β2-ARs in HF has been re-
ported.33 The increase in Gαi-protein activity may result 
partly from transcriptional upregulation of Gαi2 and likely 
contributes to the impaired βAR responsiveness associ-
ated with HF.34 A modest upregulation of Gαi2 was also 
identified in the rat model with long-term isoprenaline 
administration in our study,35 which suggests that these 
effects are an adaptive response to chronic sympathetic 
stimulation. However, in a chronic setting, these chang-
es result in reduced ventricular cardiomyocyte cAMP 
levels that decrease the activation of protein kinase A 
in HF. Together with the augmentation of global protein 
phosphatase activity in HF,36 the restricted cAMP signal-
ing results in reduced phosphorylation of key cardiac 
Ca2+-handling proteins with subsequent decreases in 
Ca2+-transient amplitude and cellular shortening,37 which 
are well-established contributors to the reduced ventricu-
lar contractility in HF.38
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Figure 8. Nucleoside diphosphate kinase (NDPK)-C interaction with G proteins shifts toward Gαi2 in heart failure (HF).  
A, Representative Western blots (top) and quantification of protein expression (middle) of NDPK-B and NDPK-C in ventricular whole-
tissue lysates obtained from explanted hearts from patients with end-stage HF or nonfailing (NF) control donor hearts. γ-Tubulin 
served as loading control. Bottom, Quantification of Gαi2 and Gαs in ventricular membrane fractions obtained from HF or NF control 
donor hearts. β-Actin served as loading control. Original blots shown in Figure IX in the online-only Data Supplement. B, Immunopre-
cipitation (IP) of NDPK-C in ventricular lysates obtained from patients with HF or NF donor hearts and quantification of the amount of 
Gαs and Gαi2 immunoprecipitating with NDPK-C relative to NF controls. IB indicates immunoblot. C, cAMP levels in ventricular samples 
of patients with end-stage HF or NF control donor hearts in the presence of 3-isobutyl-1-methylxanthine (IBMX; 1.0 mmol/L). Numbers 
in bars indicate number of hearts. From 1 HF sample, not enough lysate could be obtained for immunoprecipitation. *P<0.05 vs 
NF. D through F, Representative Western blots of Gαi2, Flag–NDPK-C, and β-actin as loading control (D), basal cAMP levels (E), and 
ISO-induced cAMP levels with EC50 values (F) in neonatal rat cardiomyocytes (NRCMs) infected with an adenovirus encoding enhanced 
green fluorescent protein (Ad-EGFP, multiplicity of infection [MOI], 500), Ad-Flag–NDPK-C (MOI, 500), Ad-Gαi2 (MOI, 50), or Ad-Flag–
NDPK-C (MOI, 500) plus Ad-Gαi2 (MOI, 50). *P<0.05 vs Ad-EGFP controls.
 #P<0.05 for the effect of Ad-Flag–NDPK-C plus Ad-Gαi2.
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Previous work has shown that the plasma membrane 
content of NDPK-A, NDPK-B, and NDPK-C is increased 
in patients with end-stage HF4 and that long-term ac-
tivation of βARs increases anchoring of NDPKs to the 
plasma membrane.39 Here, we discovered that this in-
crease is due at least in part to a transcriptional upregu-
lation and that NDPK-C is required and indispensable for 
membrane localization of NDPKs. The human nm23-H3 
gene encoding NDPK-C contains active AP-2 sites and a 
putative CREBP-1 binding site in its promoter region,40 
which are involved in cAMP-dependent regulation of 
gene transcription41,42 and could contribute to the en-
hancement of NDPK-C protein levels after isoprenaline 
administration or in end-stage human HF with chronic 
sympathetic stimulation. Further work is needed to di-
rectly test these hypotheses.
Our data on the interaction of NDPK-C with NDPK-
B and heterotrimeric G proteins also strongly suggest 
that NDPK-C is an essential prerequisite for the complex 
formation of NDPK-C/NDPK-B hetero-oligomers with G 
proteins. In addition, the lipophilic nature of NDPK-C 
may allow an easier association with the plasma mem-
brane43,44 and is therefore likely the limiting factor for 
the plasma membrane localization of NDPK isoforms.
Novelty and Potential Clinical Implications
We have identified a novel mechanism by which the 
plasma membrane content of heterotrimeric G pro-
teins is regulated in cardiomyocytes through NDPK-C. 
In particular, we show for the first time that NDPK-C is 
required and indispensable for the interaction between 
NDPKs and both stimulatory Gαs and inhibitory Gαi pro-
teins, find that NDPK-C–mediated targeting of NDPKs to 
the plasma membrane is increased in response to βAR 
stimulation and enhances intracellular cAMP levels, dem-
onstrate that cardiomyocyte contractility in vitro and in 
vivo is strictly modulated by NDPK-C levels, and provide 
novel mechanistic insights into cAMP signaling in HF, 
identifying previously unrecognized molecular targets for 
the development of new and potentially more effective 
HF therapy options. Our data put previous studies about 
regulation of cAMP signaling through NDPKs in a novel 
and conclusive perspective: NDPK-B can exert its effects 
on cAMP signaling and contractility only in the presence 
of NDPK-C, which is responsible for both the membrane 
targeting and interaction of NDPKs with G proteins. Fur-
thermore, our findings provide a potential mechanistic 
explanation for why even a small increase in Gαi2-protein 
levels and increased membrane-associated NDPKs in 
HF may inhibit cAMP synthesis14 and could cause a pro-
found negative inotropic effect. It is interesting to note 
that modest changes in the Gαs/Gαi ratio (Figure 1F), 
which are in the same range as those reported in HF,31,32 
may determine which of the G-protein subtypes is bound 
to NDPK-C. Thus, in the absence of Gαi upregulation, the 
increased membrane content of NDPK-C in human HF is 
a mechanism that could potentially counteract a fading 
βAR response in the early stages of HF by increasing the 
amount of Gαs proteins at the plasma membrane. How-
ever, by switching to Gαi2 activation, NDPK-C could play 
a role in the progression of the disease and the reduced 
cAMP levels observed in end-stage human HF. Together, 
these data provide new insights into the complex altera-
tions in G-protein signaling that are a hallmark of the vi-
cious cycle of chronic sympathetic stimulation in HF and, 
for the first time, establish increased NDPK-C function as 
a novel possible molecular facilitator of detrimental Gαi-
protein signaling in patients with HF.
Treatment with β-blockers has been the standard 
therapy for patients with HF. Despite their positive ef-
fects on morbidity and mortality, β-blockers are not 
without limitations. Accordingly, other ways to regulate 
G-protein signaling and cardiac proteins involved in car-
diac contractility are currently being investigated in the 
treatment of HF.45,46 A better understanding of the mo-
lecular processes involved in dysregulation of G-protein 
signaling in HF is expected to foster the development of 
improved HF therapies. On the basis of our studies, we 
identify NDPK-C as a novel potential therapeutic target 
involved in the regulation of aberrant G-protein signaling 
and cardiac contractility in HF. Even short-term stimula-
tion of cardiomyocytes with isoprenaline increases the 
plasma membrane content of NDPK-C and strengthens 
the interaction between NDPK-C and G proteins, thereby 
increasing cAMP synthesis. The increased expression or 
plasma membrane content of NDPK-C in human HF might 
initially allow the heart to compensate a beginning loss 
in βAR-induced contractile response in the onset of HF. 
However, because of the promiscuous nature of NDPK-
C, which is able to interact with both Gαs and Gαi, this 
compensatory mechanism might become detrimental 
for the heart when the interaction with Gi2 increases over 
time. Along these lines, we show that if Gαi2 levels are 
enhanced, an increase in NDPK-C abundance reduces 
cAMP levels (Figure 8E and 8F), which may contribute 
to the detrimental cardiomyocyte phenotype of human 
HF. Thus, inhibition of NDPK-C might represent a novel 
adjuvant therapy for patients with end-stage HF.
Limitations
The causes of HF are diverse. We used human ventricu-
lar tissue samples from a selected group of patients with 
end-stage HF. Our finding of increased NDPK-C expres-
sion may not hold true for all types and stages of HF. In 
addition, experimental conditions in vitro may not fully re-
flect the dynamic regulation of cAMP and contractility in 
vivo. For example, cAMP levels may change rapidly after 
tissue excision, and in situ cAMP levels were found to be 
similar between nonfailing patients and patients with HF, 
possibly as a result of increased plasma norepinephrine 
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levels counteracting intrinsic downregulation of cAMP in 
cardiomyocytes.47
Isoprenaline increased the plasma membrane content 
of the primarily cytosolic NDPK-C within several hours af-
ter stimulation. The mechanisms involved could include 
translocation, increased protein stability at the plasma 
membrane, or reduced degradation and should be ad-
dressed in future studies.
Here, we characterized the role of NDPK-C in mod-
ulating cAMP levels. However, as histidine kinases, 
NDPKs could also directly phosphorylate various tar-
gets within the cardiomyocyte, thereby participating in 
the control of various cardiac functions.48 For example, 
NDPK-B activates transient-receptor potential vallinoid 
type-5 channels through phosphorylation of histidine 
711, thereby controlling Ca2+ reabsorption in the kid-
ney.49 Similarly, NDPK-B activates small-conductance 
Ca2+-activated K+ channels in vascular smooth muscle 
cells, controlling neointima formation in carotid arter-
ies.50 Subsequent work should test these possibilities 
in the heart.
Conclusions
NDPK-C is indispensable for the interaction between 
NDPKs and G proteins and the anchoring of these com-
plexes at the plasma membrane, thereby dynamically 
regulating cAMP levels and cardiomyocyte contractility. 
The switch from predominantly Gαs stimulation to Gαi 
activation by NDPK-C in human HF might cause lower 
cAMP levels in patients with HF, potentially contributing 
to the progression of HF. Together, our findings position 
NDPK-C as a novel critical determinant of βAR/cAMP sig-
naling that could contribute to impaired cardiac function 
and remodeling in human HF.
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2 
Extended Methods 
Tissue procurement 
Non-failing human myocardium from the free wall of the left ventricle was obtained from 
organ donors with no apparent heart disease and normal left ventricular function (determined 
by echocardiography) for whom no suitable heart transplant recipients had been identified. 
Left ventricular myocardium of failing human hearts was obtained from patients that 
underwent cardiac transplantation due to end-stage heart failure (HF, NYHA III–IV). Patient 
characteristics are given in1 for samples used in mRNA analyses. Samples for the additional 
cohort used for Western blot analyses were obtained from 5 patients (all male, aged 
52.4±1.2 years) with end-stage HF (EF<25%) and from 6 organ donors (all male, aged 
54.5±2.7 years). The experimental protocol was approved by the Ethical Review Board of the 
Medical Center of the University of Szeged. Informed written consent was obtained for the 
use of non-diseased human hearts in this research study. All procedures conformed to the 
Helsinki Declaration of the World Medical Association. 
 
Rat model of isoprenaline-stimulation and isolation of rat cardiomyocytes 
For the rat HF model, male Wistar rats (240-300 g) received 4 days of either isoprenaline 
(2.4 mg/kg/day, ISO). Control rats received vehicle (0.9% NaCl), administered via osmotic 
minipumps (Alzet, USA), as previously described.2 NRCM and ARCM were isolated from 
normal Wistar rats using a collagenase digestion method as previously described. All 
procedures regarding care and use of animals were in accordance with institutional 
guidelines (Az. G10/65 LAVES Niedersachsen, Germany). 
 
3 
Isolation of RNA and quantification of mRNA content 
Total RNA was isolated using a high purity RNA isolation kit (Roche) from human, mouse 
and rat ventricular tissue samples, or from NRCM. The mRNA in 1 µg of total RNA was 
transcribed into cDNA using the first strand cDNA synthesis kit (Fermentas) according to the 
manufacturer’s protocol and mRNA content was quantified by real-time PCR from reverse-
transcribed cDNA samples using the Light Cycler System (Roche). Specificity of the 
reactions was confirmed using a dissociation protocol after each cycle, and comparison of 
the results with the expected melting-point temperature of the amplicon, as well as by 
verification of the expected size of the product. PCR amplifications were carried out in 
duplicates, using the following conditions: 10 minutes at 95°C, followed by a total of 35-45 
three temperature cycles (10 sec at 95°C, 10 seconds at 55°C and 25 sec at 72°C), and 5 
min at 72°C. The primers that were used are listed in Supplementary Table 1. Target genes 
were normalized using oligonucleotide primers for either, human porphobilinogen deaminase 
(PBGD), ribosomal protein L10 (RPL10) or rat hydroxymethylbilanesynthetase (HMBS) as an 
internal standard. 
 
Supplementary Table 1. Primers 
Human 
Gene Forward Reverse 
NDPK-A CAACTGTGAGCGTACCTTC GTCTTCACCACATTCAGCC 
NDPK-B TGAAGCAGCACTACATTGAC GGCTGATTTCTTTTTCAGCAC 
NDPK-C AGGTTGGCAAGAACCTGATTCAC CCTGTACGCCAGGGATTG 
Rat 
Gene Forward Reverse 
NDPK-B TGAAAGACCGTCCTTTCTTCC CTCTCCACTGAATCACTGCC 
NDPK-C CAGTGATTCGGTGGAAAGTG AAATAGAGGGTGGGATGTGG 
 
Generation of recombinant adenoviruses 
EGFP and Human cDNA of NDPK-A, NDPK-B and Flag-NDPK-C were subcloned in the 
pAdTrack or pIRES shuttle vector, and recombinant adenoviruses were generated using the 
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AdEasy system, as described.3, 4 The adenoviruses encoding EGFP, G12 (G) and LacZ 
have previously been described.5, 6 
 
Transfection and transduction 
NRCM or MEFs were infected with recombinant adenoviruses at the indicated MOI under 
serum-free conditions 48 hours after plating, and were subsequently cultured supplemented 
with 4% FCS for 48 hours. Knockdown of NDPK-C was performed using siRNA against rat 
NDPK-C (GCTTTGAAAGGAAGGGCTT) for 96 hours. Control siRNA was a scrambled 
siRNA (Ambion).5 ARCM were infected 1 hour after plating and further cultured for 24 hours 
in a HEPES-modified medium 199 (M199, Sigma S7528, supplemented with 5 mmol/L 
taurine, 5 mmol/L carnitine, 5 mmol/L creatine, 5 mmol/L N-mercaptoproprionyl glycine, 0.1 
µmol/L insulin, 10,000 U/mL penicillin and 10 mg/mL streptomycin, pH 7.25). 
 
Immunoblot analysis and co-immunoprecipitation 
Preparation of whole cell lysates, membrane fractions and zebrafish lysates has been 
described previously.7, 8 Co-immunoprecipitation and immunoblotting were performed 
according to standard procedures, as described,7, 8 by using specific antibodies against the 
Flag epitope (F3165, Sigma), Gs,olf (C-18, Santa Cruz), Gi2 (T-19, Santa Cruz), Gq (C-19, 
Santa Cruz), G1 (sc-379, Santa Cruz), G (T-20, Santa Cruz), zebrafish NDPK B (L-16, 
Santa Cruz), mammalian NDPK-B (MC-412, Kamiya, or a custom antibody generously 
provided by Edith Postel, Robert Wood Johnson Medical School, New Brunswick, NJ),9 
NDPK-C (PAB2028, Abnova, or a custom antibody generously provided by Ioan Lascu, 
University Bordeaux Segalen, France),10 -actin (AC-74, Sigma), GAPDH (5G4, HyTest), 
pan-cadherin (C1821, Sigma) and -tubulin (4D11, Thermo Scientific). Detection was 
performed with suitable secondary antibodies and an enhanced chemiluminescence (ECL) 
reagent (Thermo Scientific). Protein bands were visualized with a FluorS-MultImager (Bio-
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Rad) or a ChemoCam Imager (Intas) and quantified using ImageJ software. The signal 
intensity of the indicated loading control was used for normalization. For calibration of the 
amounts of Gs or Gi2 in Western blots, fluorescent secondary antibodies were used and 
visualized using Odyssey CLx (Licor).  
 
Preparation of membrane fractions 
Preparation of highly-purified sarcolemma from ventricular tissue samples obtained from 
human HF and NF patients was performed as previously described.8 NRCM or MEFs were 
homogenized twice for 15 seconds in a buffer containing 10 mmol/L Tris-HCl, pH 7.4 and 1 
mmol/L EDTA with a homogenizer at 20,000 rpm interrupted by a 30 seconds cooling period 
on ice. To obtain membrane fractions, the homogenate was cleared from debris and nuclei 
by centrifugation at 600 g for 5 minutes. Subsequently, membranes were pelleted at 100,000 
g for 30 minutes at 4°C. 
 
Far Western blotting 
Purified heterotrimeric G protein transducin Gt recombinant NDPK-B, or NDPK-C 
(Genway) were spotted on a nitrocellulose membrane and blocked in Roti-Block® for 1 hour 
at room temperature. The membrane was incubated with 200 µg of cell lysate obtained from 
MEFs or NRCM infected with either Ad-EGFP (MOI 100), Ad-NDPK-B (MOI 100), or Ad-
NDPK-B (MOI 100) plus NDPK-C with increasing MOIs (3-100), for 2 hours. For interaction 
assay between Gs or Gi2 and NDPK-C, the membrane was incubated with a total amount 
of 150 µg cell lysate obtained from different combinations of NRCM infected with Ad-EGFP 
(MOI 50), Ad-Gs (MOI 50), Ad-Gi2 (MOI 50), or Ad-G12 (MOI 50). The membrane was 
washed 9 times for 10 minutes and followed by Western blot procedures. To estimate the 
amount of Gs and Gi2 that interact with NDPK-C, 1000 ng, 500 ng, 80 ng or 50 ng of 
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recombinant Gs and Gi2 (Calbiochem) were blotted and a standard curve was determined 
based on the integrated density of the bands. 
 
ATP hydrolysis and GTP hydrolysis assays 
The assays were performed as previously described.11-13 In brief, 1 µmol/L purified 
heterotrimeric G protein transducin Gt, 0.5 - 2 µmol/L recombinant NDPK-B or 0.25 - 0.5 
µmol/L recombinant NDPK-C (Genway) were incubated in the reaction buffer containing 0.5 
mmol/L MgCl2, 0.1 mmol/L EGTA, 1 mmol/L dithiothreitol and 0.2% (w/v) bovine serum 
albumin in 50 mmol/L triethanolamine/HCL, pH 7.4. For ATP hydrolysis, 0.5 µmol/L [-
32P]ATP (0.1 µCi/tube), 50 µmol/L ATP, and 0.5 µmol/L GDP were added to the reaction 
buffer. For GTP hydrolysis 0.5 µmol/L [-32P]GTP (0.1 µCi/tube) and 50 µmol/L GTP were 
added to the reaction buffer. To inhibit the effect of NDPKs on ATP hydrolysis, 500 µmol/L 
UDP was added to the reaction tubes, as described.14 The reaction tubes were incubated for 
40 minutes at 30°C. The reaction was stopped by adding ice cold sodium phosphate buffer 
(20 mmol/L, pH 2.0) with 5% (w/v) activated charcoal followed by centrifugation at 10,000 g 
for 10 min. The amount of [32P]Pi release was determined in 500 µL of the supernatant in 3 
mL water using the Tri-Carb liquid scintillation analyzer (Packard). 
 
Visualization of the subcellular localization of NDPK C 
NRCM and ARCM were cultured with serum free medium on coverslips for 12 hours and 
infected with Ad-Flag-NDPK-C at a MOI of 50. 24 hours later, the cells were stimulated with 
solvent or 1 µmol/L ISO for up to 6 hours. The medium was withdrawn and the cells were 
washed twice with phosphate buffered saline (PBS) and fixed with 4% paraformaldehyde for 
10 minutes. After fixation, cells were permeabilized with 0.1% Triton X-100 in PBS for 10 
minutes, treated with Roti-Block (Roth) for 1 hour and incubated with the anti-Flag antibody 
at a dilution of 1:1000 in PBS containing 0.1% Tween 20 (Tween-PBS) for 3 hours at RT. 
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The coverslips were washed 3 times with Tween-PBS and incubated with the Cy3 labeled 
secondary antibody (1:200 dilution, Dianova) for 1 hour in a humidified chamber protected 
from light. The coverslips were again washed twice with Tween-PBS and mounted with 
Vectashield containing DAPI. The subcellular localization of NDPK-C was subsequently 
visualized by confocal fluorescence microscopy at the Nikon Imaging Center, University of 
Heidelberg, Heidelberg, Germany. 
 
Measurement of intracellular cAMP 
Generation of cAMP in NRCM or Zebrafish lysate was assayed as previously described 
using a cAMP immunoassay (Assay Designs or Cayman Chemical).5, 7, 15 cAMP was also 
assayed in living ARCM that were isolated as previously described, plated on laminin-coated 
glass coverslips and transduced with Epac2-camps adenovirus6 at MOI 300 together with 
either a control (LacZ) or a Flag-NDPK-C-encoding adenovirus at the same MOI. 48 hours 
later, cells were washed once and maintained in a physiological buffer containing 144 
mmol/L NaCl, 5.4 mmol/L KCl, 1 mmol/L CaCl2, 1 mmol/L MgCl2, and 20 mmol/L HEPES, pH 
7.4 at room temperature, placed on a Zeiss Axio Observer A1 microscope equipped with 
Plan-Apochromat 63x/1.4 oil immersion objective, Polychrome V light source, DV2 DualView 
beam splitter and CoolSNAP-HQ2 CCD-camera (Visitron Systems, Puchheim, Germany). 
Cells were stimulated with ISO, forskolin and 3-isobutyl-1-methylxanthine (IBMX; all from 
Sigma). The YFP/CFP emission ratio was monitored upon 436 nm excitation (filters YFP 535 
± 15 nm, CFP 480 ± 20 nm). After each measurement, emission values were corrected for 
bleed-through of CFP into YFP channel and for photo-bleaching as described.16 The imaging 
data were acquired using the VisiView software (Visitron) and analyzed with Excel and Origin 
8.5 (OriginLab) packages.  
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Fractional shortening in ARCM 
ARCM were infected with Ad-EGFP or Ad-Flag-NDPK C at a MOI of 300 for 24 hours. 
Thereafter, sarcomere shortening was assessed on field stimulation (1 Hz with 4 ms 
duration, 20 V bipolar) using a video-based sarcomere length detection system (IonOptix) at 
1 mmol/L Ca2+ in the bath solution. Myocytes were exposed to increasing concentrations of 
ISO (0.1 to 300 nmol/L). Sarcomere length measurements were performed at room 
temperature on intact, rod-shaped cells, which had no spontaneous contractions or 
microblebs, as previously described.17 
 
Zebrafish maintenance, MO-injection, measurement of fractional shortening 
and histology 
Zebrafish danio rerio (TE4/6 strain) were maintained under standard conditions.17 
Morpholino-modified oligonucleotides (Gene Tools, USA) were directed against the splice-
donor site of exon2 (MO-NDPK-C: 5’-ATGCTGTATTAGGGTTCTCACCTGC) of zebrafish 
NDPK-C or against the translation start site of zebrafish NDPK-B 
(5’-GGTGCGCTCGGTCTTAGCAGACATG).7 Embryos at one-cell stage were injected with 
the indicated amounts of morpholino or a standard control oligonucleotide (MO-Ctl, 
Genetools, LCC) at the same concentration. For rescue experiments, embryos were injected 
with NDPK-C morpholino and/or NDPK-B mRNA (130 ng/µL) and phenotypic abnormalities 
(pericardial edema, macroscopic morphological abnormalities, and/or macroscopic cardiac 
dysfunction; Supplementary Figure 7) were assessed. Injections and analyses were 
performed as previously described.7 Still images and video films were recorded and digitized 
with a Zeiss microscope/MCU II. Fractional shortening (FS) and ventricular diameters were 
assayed as described. For sectioned hematoxylin/eosin- and whole mount immunostainings, 
embryos were fixed in 4% paraformaldehyde. Sections were stained with or incubated with 
the indicated antibody (S46; MF20), as described.17 For electron microscopy embryos were 
pre-fixed with 3% glutaraldehyde and 0.1% picric acid in 0.1 mol/L sodium cacodylate, and 
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post-fixed in 1% OsO4. Samples were embedded in Epon (Serva) according to standard 
procedure and electron micrographs of fish embryos were obtained as described.17 
 
Chronic isoprenaline administration, echocardiography and collagen staining 
in control and NDPK-B knock-out mice 
The study was performed with 2 or 5 months old male C57Bl/6 NDPK-B-/- and NDPK-B+/+ 
littermates.18 ISO (Sigma-Aldrich) was delivered to 2 months old mice through 
subcutaneously implanted osmotic minipumps (Alzet, model 1007D) that released ISO in 
0.9% NaCl at a dose of 30 mg/kg/d.19 For the procedure animals were anesthetized with 2% 
isoflurane inhalation and received carprofen (5 µg/kg s.c.) as analgesic. All procedures 
regarding care and use of animals were in accordance with institutional guidelines and 
authorized by the Regierungspräsidium Karlsruhe, Germany (AZ: G-12\10). After 7 days 
cardiac function was monitored by 2D echocardiography (Sonos 5500) on conscious mice, 
as described previously.20 M-mode tracings were used to measure left ventricular internal 
end-diastolic (LVEDD) and end-systolic diameters (LVESD). The % fractional shortening 
(FS) was calculated using FS (%) = ((LVEDD-LVESD)/LVEDD) * 100. Animals were 
subsequently sacrificed and hearts were harvested for further analysis. Middle transverse 
heart sections (1 mm) were fixed in 4% formaldehyde (4°C, overnight) and embedded in 
paraffin. Deparaffination, rehydration and staining of 10 µm sections were performed 
according to the manufacturer’s instructions (Sirius Red/Fast Green Collagen Staining Kit, 
Chondrex). Collagen content was determined by ImageJ and normalized to the total tissue 
area. 
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Supplementary Figures 
 
Supplementary Figure 1. Kyte-Doolitle plot of NDPK-C and sequence alignment of N-
terminal domains of NDPK-A, NDPK-B and NDPK-C showing the hydrophobicity of the 
NDPK-C N-terminal domain.  
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Supplementary Figure 2. NDPK-C regulates GTPase activity of the heterotrimeric G protein 
transducin (Gt. GTP hydrolysis was determined by the amount of [
32P]Pi release in the 
presence of 1 µmol/L GtGt2 µmol/L NDPK-B, Gt0.5 µmol/L NDPK-C, or 
GtNDPK-B + NDPK-C. *P<0.05 vs. Gt; 
#P<0.05 vs. Gt + NDPK-B. 
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Supplementary Figure 3. Calibration of the amounts of Gs or Gi2 in Western blots of 
NRCM lysates. A, Representative Western blots of Gs and GAPDH in control (CTL) 
NRCMs, NRCMs overexpressing Gs and 80 ng recombinant Gs (top) and Western blot of 
500 ng or 1000 ng recombinant Gs (middle) that were employed to create a calibration 
curve for Gs (bottom). B, Similar to panel A for Gi2. 
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Supplementary Figure 4. NDPK-C expression is increased in heart failure (HF). A, 
Representative Western blots of increasing amounts of purified NDPK-A, -B, or -C and 
plasmalemmal fractions of ventricular samples obtained from hearts explanted from patients 
with end-stage HF or non-failing (NF) donor hearts. B, mRNA content of NDPK-A, -B , and -
C in ventricular samples from patients with HF or NF controls. All heart samples were 
obtained from the patient cohort described in Lutz et al.1 
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Supplementary Figure 5. NDPK-C/G interaction is enhanced following ISO stimulation. A, 
Immunoprecipitation of Flag-NDPK-C in lysates obtained from NRCM infected with Ad-Flag-
NDPK-C (MOI=500) after stimulation with 1.0 μmol/L ISO for the indicated time. B, Similar to 
panel A for Flag-NDPK-C co-immunoprecipitating with G. Co-immunoprecipitation was 
detected using antibodies against Flag-NDPK-C and G. 
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Supplementary Figure 6. Structural properties of zebrafish hearts. A,C, Histology sections 
of a representative control morpholino-injected zebrafish heart (A) and a zebrafish heart with 
morpholino-induced NDPK-C knockdown (C) stained with hematoxylin/eosin. Morphants 
display normal heart morphology with distinct endocardial and myocardial cell layers in 
atrium and ventricle. A, atrium, V, ventricle, en, endocardial layer, my, myocardial layer. B,D, 
Whole mount immunofluorescence following staining with specific antibodies against atrial 
myosin heavy chain (S46) and entire heart tube myosin heavy chain (MF20) showing 
unaltered expression of structural proteins in control (B) or NDPK-C knockdown (D) zebrafish 
hearts. E,F, Transmission electron microscopy of a control (E) and a NDPK-C knockdown (F) 
heart at 72 hpf. The sarcomeres of cardiomyocytes of NDPK-C morphant hearts show no 
ultrastructural differences. 
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Supplementary Figure 7. Lateral view of representative zebrafish larvae injected with 
control morpholino (MO-Ctl), with NDPK-C morpholino (MO-NDPK-C), or with MO-NDPK-C 
with concomitant increase in NDPK-B expression (MO-NDPK-C + mRNA NDPK-B) at 72 
hours post fertilization exhibiting a normal phenotype (top row) or phenotypic abnormalities 
(bottom row). 
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Supplementary Figure 8. Ablation of NDPK-B has no impact on NDPK-C mRNA or protein 
levels. A, quantitative PCR of NDPK-C transcripts normalized to RPL10. Values are given 
relative to wildtype (WT) control. B, representative immunoblot of NDPK-A, B, and C and 
quantification of NDPK-C expression levels normalized to pan-cadherin. Lysates prepared 
from ventricular myocardium were analyzed by immunoblot and probed with an antibody 
detecting indicated isoforms of NDPKs. Values are given relative to WT control. 
  
18 
 
Supplementary Figure 9. Expression and interaction of NDPKs and G proteins in human 
end-stage heart failure (HF). A, Representative Western blots (top), and quantification of 
protein expression (bottom) of Gi2 and Gs in ventricular membrane fractions obtained from 
explanted hearts from patients with end-stage HF or non-failing (NF) control donor hearts. -
actin served as loading control. The bar chart is also shown in Figure 8A. B, 
Immunoprecipitation of Gs or Gi2 in ventricular lysates obtained from HF patients or NF 
donor hearts and quantification of immunoprecipitated NDPK-C, relative to NF controls. 
Numbers in bars indicate number of hearts. From one HF sample not enough lysate could be 
obtained for immunoprecipitation. 
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Supplementary Videos 
Supplementary Video 1. Control morpholino-injected zebrafish embryo at 72 hpf. After 72 
hours of development, cardiac chambers contract vigorously in wild-type (WT) zebrafish 
embryos. 
 
Supplementary Video 2. NDPK-C knockdown zebrafish embryo at 72 hpf. NDPK-C 
expression was inhibited by injection of Morpholino-modified antisense oligonucleotides (MO) 
against NDPK-C. After 72 h of development, MO-NDPK-C injected embryos suffer from 
severely impaired cardiac contractility of the ventricle. 
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